Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer.

BACKGROUND This study assesses the efficacy of epirubicin and docetaxel as neoadjuvant therapy for women with breast cancer. PATIENTS AND METHODS This is a single institution, single arm, phase II study of epirubicin given at 75 mg/m(2) and docetaxel at 75 mg/m(2) every three weeks for four cycles prior to surgical excision in women with large breast… (More)